Secular Trends in the Prevalence of Total and Latent Prostate Cancer over Half a Century According to Consecutive Autopsy Cases in a Japanese community: The Hisayama Study

根据日本某社区连续尸检病例,半个世纪以来前列腺癌总发病率和潜伏性前列腺癌患病率的长期趋势:久山研究

阅读:2

Abstract

BACKGROUND AND OBJECTIVE: Our aim was to investigate secular trends in the period prevalence of total prostate cancer (PC) and latent PC (LPC) according to consecutive autopsy cases in a Japanese community. METHODS: A total of 1355 deceased men aged >40 yr in a Japanese community underwent consecutive autopsy examination between 1962 and 2020. The period prevalence of total PC and of LPC was calculated for 15-yr intervals, and secular trends were analyzed using a logistic regression model. KEY FINDINGS AND LIMITATIONS: The period prevalence of both total PC (from 1.7% in 1962-1976 to 19% in 2007-2020; p < 0.001) and LPC (from 1.3% in 1962-1976 to 11% in 2007-2020; p < 0.001) significantly increased over time (p (trend) < 0.001). The age-specific period prevalence of total PC also increased for the age groups 60-79 yr (from 0.55% in 1962-1976 to 9.8% in 2007-2020; p = 0.005) and ≥80 yr (from 6.5% in 1962-1976 to 26% in 2007-2020; p = 0.003). There was no evidence of a secular change in the pathology of LPC. CONCLUSIONS AND CLINICAL IMPLICATIONS: The period prevalence of autopsy-proven total PC and LPC increased over the past 60 yr in a Japanese community. It is likely that this upward trend has involved additional factors beyond improvements in screening and diagnostic techniques or the aging of the population. PATIENT SUMMARY: We used data from autopsy examinations in a Japanese population to analyze long-term trends for the occurrence of prostate cancer. We found a significant rise in the occurrence of both diagnosed prostate cancer and latent prostate cancer over the past 60 years in this Japanese community.

特别声明

1、本页面内容包含部分的内容是基于公开信息的合理引用;引用内容仅为补充信息,不代表本站立场。

2、若认为本页面引用内容涉及侵权,请及时与本站联系,我们将第一时间处理。

3、其他媒体/个人如需使用本页面原创内容,需注明“来源:[生知库]”并获得授权;使用引用内容的,需自行联系原作者获得许可。

4、投稿及合作请联系:info@biocloudy.com。